Is STAAR Surgical Co. overvalued or undervalued?

As of 11 February 2025, the valuation grade for STAAR Surgical Co. has moved from very expensive to risky. The company appears to be overvalued given its current financial metrics. Key ratios include a Price to Book Value of 2.53, an EV to Sales ratio of 2.39, and a ROCE of -51.79%.
In comparison with peers, STAAR Surgical Co. has a significantly negative EV to EBITDA of -11.15, while AtriCure, Inc. shows a worse EV to EBITDA of -428.4065, and Pacific Biosciences of California, Inc. has a less negative EV to EBITDA of -3.5297. The company's recent stock performance has been poor, with a year-to-date return of -31.33%, contrasting sharply with the S&P 500's gain of 2.44% during the same period, reinforcing the notion that STAAR Surgical Co. is overvalued in the current market environment.